Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsGlobe Newswire • 11 months agoLast Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on ...